Brivaracetam
- Generic Name
- Brivaracetam
- Brand Names
- Briviact, Briviact (in Italy: Nubriveo)
- Drug Type
- Small Molecule
- Chemical Formula
- C11H20N2O2
- CAS Number
- 357336-20-0
- Unique Ingredient Identifier
- U863JGG2IA
- Background
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
- Indication
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- -
Axonis raises $115 million to overcome drug resistance in epilepsy
Axonis, launched in 2020, aims to enhance KCC2 protein effectiveness for epilepsy and pain treatment, with clinical testing planned for 2023. The company secured funding to advance its lead program and explore psychiatric and neurodevelopmental disorder treatments. The epilepsy drug market is projected to grow from $10.15 billion in 2022 to $15.35 billion by 2030.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath